QuidelOrtho Corp (QDEL) stock
Close on Nov 17, 2026Market cap $676.84MP/E –Yield –
QuidelOrtho Corp saw revenue fall 4.5% to $2.59B over the twelve months to Sep 27, 2026. Free cash flow was -$117.10M. At the latest close the market valued the company at $676.84M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 27, 2026
Valuation
- Market cap
- $676.84M
- P/E ratio
- –
- Price to sales
- 0.26
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- -17.30%
Fundamentals
- Revenue
- $2.59B
- Net income
- -$369.20M
- EPS, diluted
- -$5.41
- Free cash flow
- -$117.10M
- Book value per share
- $26.07
- Diluted shares
- 69M
Trading
- Next earnings
- Feb 10, 2027 (estimated, after the close)
- Previous close
- $10.21
- Open
- $10.15
- Day's range
- $9.82 – $10.64
- Volume
- 7,719,583
- Average volume (20 days)
- 2,651,882
- Index membership
- S&P SmallCap 600 (since Aug 2024), Russell 2000 (since Jun 2025), Russell 3000 (since May 2022)
- 52-week range
- $9.92 – $35.58
- RSI (14 days)
- 36.7
- Volatility (1 year)
- 91.4%
- Relative volume
- 1.10×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | QDEL | S&P 500 | Difference | QDEL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | -4.0% | −19.5 pts | ||
| 3 months | -32.3% | -5.0% | −27.3 pts | ||
| Year to date | -65.4% | +8.2% | −73.7 pts | ||
| 1 year | -53.2% | +11.2% | −64.4 pts | ||
| 3 years | -85.1% | +68.5% | −153.6 pts | -47.0% | +19.0% |
| 5 years | -93.4% | +67.3% | −160.7 pts | -41.9% | +10.8% |
| 10 years | -55.5% | +291.6% | −347.2 pts | -7.8% | +14.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases QuidelOrtho filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Results
About QuidelOrtho
In Vitro & In Vivo Diagnostic Substances
QuidelOrtho Corporation develops diagnostic testing solutions, laboratory instruments, and related services. Its business units comprise Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics, organized geographically into North America, EMEA, China, JPAC, and Latin America. Offerings include clinical chemistry systems, immunoassays, blood typing instruments, donor screening assays, molecular testing platforms, and rapid point-of-care tests, supplemented by informatics software. Customers include hospitals, clinical laboratories, reference labs, physician offices, urgent care and retail clinics, pharmacies, blood banks, donor centers, and over-the-counter consumers.
Company profile, executives and historyQuidelOrtho stock: common questions
What is QuidelOrtho's stock price?
QDEL closed at $9.87 on Nov 17, 2026, down 3.33% on the day. Over the past 52 weeks it traded between $9.92 and $35.58.
What is QuidelOrtho's market cap?
QuidelOrtho was worth $676.84M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is QDEL's P/E ratio?
QuidelOrtho lost money over the twelve months to Sep 27, 2026 (diluted EPS -$5.41), so it has no meaningful P/E ratio.
How much revenue does QuidelOrtho make?
QuidelOrtho reported revenue of $2.59B for the twelve months to Sep 27, 2026, down 4.5% from a year earlier.
Does QuidelOrtho pay a dividend?
No. QuidelOrtho has not paid a cash dividend over the last twelve months.
When does QuidelOrtho report earnings next?
QuidelOrtho is expected to report Q4 FY2026 results on Feb 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has QDEL stock performed over the past year?
Including dividends, QDEL returned -53.2% over the past year, against +11.2% for the S&P 500.
How many QDEL shares are sold short?
14M shares were sold short at the latest FINRA report, 37.27% of the float, or 7.6 days of average trading volume.
Who are QuidelOrtho's competitors?
Companies most similar to QuidelOrtho by business, industry and size include IDXX, NEOG, LNTH, QGEN, MYGN.
See a number that looks wrong?